169 related articles for article (PubMed ID: 34060947)
1. Surgical Resection After Talimogene Laherparepvec for Melanoma: Persistent Fuorodeoxyglucose Avidity on Positron Emission Tomography Despite No Viable Disease.
MacArthur TA; Fahy AS; Jakub JW
Am Surg; 2021 Jun; 87(6):849-854. PubMed ID: 34060947
[TBL] [Abstract][Full Text] [Related]
2. Real-World Outcomes of Talimogene Laherparepvec Therapy: A Multi-Institutional Experience.
Louie RJ; Perez MC; Jajja MR; Sun J; Collichio F; Delman KA; Lowe M; Sarnaik AA; Zager JS; Ollila DW
J Am Coll Surg; 2019 Apr; 228(4):644-649. PubMed ID: 30690076
[TBL] [Abstract][Full Text] [Related]
3. Talimogene Laherparepvec (TVEC) for the Treatment of Advanced Melanoma: A Single-Institution Experience.
Perez MC; Miura JT; Naqvi SMH; Kim Y; Holstein A; Lee D; Sarnaik AA; Zager JS
Ann Surg Oncol; 2018 Dec; 25(13):3960-3965. PubMed ID: 30298318
[TBL] [Abstract][Full Text] [Related]
4. Complete response with talimogene laherparepvec in recurrent melanoma of the ear: A case report.
Hsu AC; Kokot NC; Eisenberg BL; Thomas JS
Oral Oncol; 2020 Dec; 111():104899. PubMed ID: 32665184
[TBL] [Abstract][Full Text] [Related]
5. False positive FDG uptake in melanoma patients treated with talimogene laherparepvec (T-VEC).
Mulder EEAP; Stahlie EHA; Verver D; Lemstra C; Been LB; Mooyaart AL; Brabander T; Vegt E; Verburg FA; van der Veldt AAM; Verhoef C; van Akkooi ACJ; Grünhagen DJ
J Surg Oncol; 2021 Dec; 124(7):1161-1165. PubMed ID: 34235758
[TBL] [Abstract][Full Text] [Related]
6. Ultrasound-guided Intralesional Injection of Talimogene laherparepvec (Imlygic) for Advanced Melanoma: Technical Note on a Preliminary Experience.
Burke LMB; Yu H; Burke K; Gwynn M; Louie RJ; Ollila DW; Rn PL; Collichio F
Cardiovasc Intervent Radiol; 2021 May; 44(5):801-806. PubMed ID: 33447922
[TBL] [Abstract][Full Text] [Related]
7. Practical clinical guide on the use of talimogene laherparepvec monotherapy in patients with unresectable melanoma in Europe.
Gutzmer R; Harrington KJ; Hoeller C; Lebbé C; Malvehy J; Öhrling K; Downey G; Dummer R
Eur J Dermatol; 2018 Dec; 28(6):736-749. PubMed ID: 30698145
[TBL] [Abstract][Full Text] [Related]
8. Real-World Use of Talimogene Laherparepvec in German Patients with Stage IIIB to IVM1a Melanoma: A Retrospective Chart Review and Physician Survey.
Mohr P; Haferkamp S; Pinter A; Weishaupt C; Huber MA; Downey G; Öhrling K; Loquai C; Louie KS
Adv Ther; 2019 Jan; 36(1):101-117. PubMed ID: 30536143
[TBL] [Abstract][Full Text] [Related]
9. Talimogene laherparepvec pseudolymphomatous reaction mimicking metastatic melanoma.
Henning A; Agnese D; Chung CG
J Cutan Pathol; 2021 Nov; 48(11):1423-1426. PubMed ID: 34189749
[TBL] [Abstract][Full Text] [Related]
10. Chronic granulomatous dermatitis induced by talimogene laherparepvec therapy of melanoma metastases.
Everett AS; Pavlidakey PG; Contreras CM; De Los Santos JF; Kim JY; McKee SB; Kaufman HL; Conry RM
J Cutan Pathol; 2018 Jan; 45(1):48-53. PubMed ID: 28940544
[TBL] [Abstract][Full Text] [Related]
11. Intratumoral talimogene laherparepvec injection with concurrent preoperative radiation in patients with locally advanced soft-tissue sarcoma of the trunk and extremities: phase IB/II trial.
Monga V; Miller BJ; Tanas M; Boukhar S; Allen B; Anderson C; Stephens L; Hartwig S; Varga S; Houtman J; Wang L; Zhang W; Jaber O; Thomason J; Kuehn D; Rajput M; Metz C; Zamba KD; Mott S; Abanonu C; Bhatia S; Milhem M
J Immunother Cancer; 2021 Jul; 9(7):. PubMed ID: 34330766
[TBL] [Abstract][Full Text] [Related]
12. Response to the Rechallenge With Talimogene Laherparepvec (T-VEC) After Ipilimumab/Nivolumab Treatment in Patient With Cutaneous Malignant Melanoma Who Initially Had a Progression on T-VEC With Pembrolizumab.
Afzal MZ; Shirai K
J Immunother; 2019 May; 42(4):136-141. PubMed ID: 30933044
[TBL] [Abstract][Full Text] [Related]
13. Future Directions and Challenges Facing Intralesional Immunotherapy With Talimogene Laherparepvec for Advanced Melanoma.
Queen D; Samie FH; Zeitouni NC
Dermatol Surg; 2021 Jan; 47(1):132-133. PubMed ID: 31574028
[No Abstract] [Full Text] [Related]
14. Regression of mucosal melanoma following intralesional talimogene laherparepvec (T-VEC) injection in combination with immunotherapy.
Drescher C; Drexler K; Hilber H; Schmidt B; Haferkamp S
J Dtsch Dermatol Ges; 2019 Mar; 17(3):321-323. PubMed ID: 30698924
[No Abstract] [Full Text] [Related]
15. Economic Evaluation of Talimogene Laherparepvec Plus Ipilimumab Combination Therapy vs Ipilimumab Monotherapy in Patients With Advanced Unresectable Melanoma.
Almutairi AR; Alkhatib NS; Oh M; Curiel-Lewandrowski C; Babiker HM; Cranmer LD; McBride A; Abraham I
JAMA Dermatol; 2019 Jan; 155(1):22-28. PubMed ID: 30477000
[TBL] [Abstract][Full Text] [Related]
16. Complete response of Merkel cell carcinoma with talimogene laherparepvec (TVEC) monotherapy.
Casale F; Tchanque-Fossuo C; Stepenaskie S; Durkin J
Dermatol Online J; 2022 Jan; 28(1):. PubMed ID: 35499413
[TBL] [Abstract][Full Text] [Related]
17. Local intralesional talimogene laherparepvec therapy with complete local response in oral palatine mucosal melanoma: a case report.
Chitnis SD; Seim NB; Kendra K
J Med Case Rep; 2024 May; 18(1):257. PubMed ID: 38778387
[TBL] [Abstract][Full Text] [Related]
18. Talimogene Laherparepvec Use in Kidney Transplant Recipient.
Gupta M; Brennan DC; Alhamad T
Transplantation; 2020 Apr; 104(4):e109-e110. PubMed ID: 31815902
[No Abstract] [Full Text] [Related]
19. The histological spectrum of talimogene laherparepvec (TVEC) injections-Neutrophilic and chronic granulomatous dermatitis.
Lee K; Pouldar D; Shiu J; Elsensohn A; de Feraudy S
J Cutan Pathol; 2019 Feb; 46(2):165-167. PubMed ID: 30414194
[No Abstract] [Full Text] [Related]
20. Randomized, Open-Label Phase II Study Evaluating the Efficacy and Safety of Talimogene Laherparepvec in Combination With Ipilimumab Versus Ipilimumab Alone in Patients With Advanced, Unresectable Melanoma.
Chesney J; Puzanov I; Collichio F; Singh P; Milhem MM; Glaspy J; Hamid O; Ross M; Friedlander P; Garbe C; Logan TF; Hauschild A; Lebbé C; Chen L; Kim JJ; Gansert J; Andtbacka RHI; Kaufman HL
J Clin Oncol; 2018 Jun; 36(17):1658-1667. PubMed ID: 28981385
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
